TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T. Tagawa(Cornell University), Petros Grivas(Seattle Cancer Care Alliance), Arash Rezazadeh Kalebasty(University of California, Irvine), Manojkumar Bupathi(Rocky Mountain Cancer Centers), Rohit Jain(Moffitt Cancer Center), Philippe Beuzeboc(Hôpital Foch), Yohann Loriot(Institut Gustave Roussy), Trishna Goswami(Gilead Sciences (United States)), Daniel P. Petrylak(Yale University), Loretta M. Itri(National Institutes of Health), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Arjun Vasant Balar(NYU Langone Health), Damien Pouessel(Institut Claudius Regaud), Phillip L. Palmbos(University of Michigan), Neeraj Agarwal(University of Utah), Philippe Barthélémy(Institut de Cancérologie Strasbourg), Aude Fléchon(Institut Català d'Ornitologia), Quan Hong(Gilead Sciences (United States)), Cora N. Sternberg(Cornell University)
Cited by 530
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k